Conmed (CNMD) Price & Analysis
CNMD Stock Chart & Stats
- Day’s Range
- MXN 863.99 - MXN 863.99
- 52-Week Range
- MXN 625.41 - MXN 1,135.06
- Previous Close
- MXN 863.99
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 24.80B
- Enterprise Value
- MXN 2.16B
- Total Cash (Recent Filing)
- MXN 47.97M
- Total Debt (Recent Filing)
- MXN 815.87M
- Price to Earnings (P/E)
- 18.3
- Beta
- -0.06
- Next Earnings
- Feb 03, 2027
- EPS Estimate
- 23.59
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Organic Growth Platforms
Growth is supported by identifiable platforms rather than a single product, with AirSeal, Buffalo Filter, and BioBrace positioned across minimally invasive surgery, smoke evacuation, and orthopedic repair. This diversified portfolio can support adoption and recurring procedure-linked demand over coming quarters.
Structural Smoke-Evacuation Demand
Expanding smoke-free operating-room regulation creates a durable demand tailwind for Buffalo Filter and related products. Requirements affecting hospitals and ambulatory surgery centers can accelerate adoption, broaden the addressable market, and make growth less dependent on discretionary purchasing alone.
Improving Margins
Improving gross and operating margins indicate better product mix and operating discipline, while management expects further full-year gross-margin expansion. Sustained margin gains would strengthen earnings resilience and provide additional internal capacity to invest in products, commercialization, and growth initiatives.
Bears Say
Revenue Contraction
The sharp TTM revenue decline signals that recent growth has not yet translated into consistent reported sales expansion. Strategic GI exits and weaker areas such as U.S. orthopedics reduce near-term scale, making earnings more exposed if newer growth platforms do not offset lost revenue.
Weaker Cash-Flow Trend
ConMed remains cash generative, but the deterioration in free-cash-flow momentum reduces the cushion available for debt service, acquisitions, and product investment. If revenue weakness persists, weaker conversion could limit capital-allocation flexibility even while reported profitability improves.
Debt And Interest Burden
A sizeable debt load and higher refinancing-related interest expense can absorb more operating cash and constrain strategic flexibility. This matters more when revenue and cash-flow trends are uneven, because weaker earnings would leave less room to fund growth or pursue acquisitions without increasing financial pressure.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
What is Conmed’s market cap?
When is Conmed’s upcoming earnings report date?
How were Conmed’s earnings last quarter?
Is Conmed overvalued?
Does Conmed pay dividends?
What is Conmed’s EPS estimate?
How many shares outstanding does Conmed have?
What happened to Conmed’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Conmed?
What is the TipRanks Smart Score and how is it calculated?
Conmed Stock Smart Score
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Patrick J. Beyer
- Employees
- 3,900
- Website
- www.conmed.com
- Address
- 11311 Concept Boulevard, Largo, FL, 33773, US
Conmed (CNMD) Earnings & Revenues
CNMD Company Deck
CNMD Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. Third-quarter organic revenue growth was 6.7%, both major product lines grew organically, AirSeal, direct Buffalo Filter, and BioBrace performed well, and adjusted EPS exceeded expectations with higher full-year EPS guidance. The main negatives were declining reported revenue and adjusted EPS, lower free cash flow, weaker U.S. orthopedic and OEM smoke-evacuation sales, higher interest expense, tariff exposure, and a narrowed high end of revenue guidance. Overall, the highlights significantly outweighed the lowlights.
View all MX:CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 2 | 5 |
| Technical Analysis | 2 | 2 | 4 |
| Moving Averages | 11 | 0 | 1 |